TMEM106B and dementia: Treatments that converge on reacidifying lysosomes have shown promise in whole animal models of LSDs [68] and dementia [69,70], where risk factors for dementias such as the lysosomal size-determinant TMEM106B [5,71] have been found to stabilize the V-ATPase [4] at the lysosome.